Recent Articles from GlobeNewswire

ING Group 2026 SREP process completed

LONDON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- STACK Infrastructure (“STACK”), the digital infrastructure partner to the world’s most innovative companies and a leading global developer and operator of data centers, today announced the appointment of Jim Smith as Chief Executive Officer of STACK EMEA.  

Guangxi Zhuang Autonomous Region Healthcare Security Administration

NEWS RELEASE                                    October 27, 2026

Medidata is the only company exclusively dedicated to clinical trial technology recognized in the Leaders category

Equinor (OSE: EQNR, NYSE: EQNR) will on 29 October 2026 commence the fourth tranche of up to USD 1,125 million of the share buy-back programme for 2026, as announced in connection with the company’s third quarter results on 28 October 2026.

Key information relating to the cash dividend to be paid by Equinor ASA (OSE: EQNR, NYSE: EQNR) for third quarter 2026.

Equinor (OSE:EQNR, NYSE:EQNR) delivered an adjusted operating income* of USD 12.35 billion in the third quarter of 2026. Equinor reported a net operating income of USD 11.95 billion and a net income of USD 2.54 billion. Adjusted net income* was USD 2.86 billion, leading to adjusted earnings per share* of USD 1.20.

SHANGHAI, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the final analysis results from the Phase 3 NEOTORCH study (NCT04158440) were presented during an oral session at the 2026 European Society for Medical Oncology (ESMO) Congress (Abstract No. LBA64) and simultaneously published in Annals of Oncology. Professor Shun LU and Professor Ziming LI from Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine served as the corresponding author and first author of the publication, respectively.

GUANGZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, today announced the launch of its global insurance partnership program to support the expansion of autonomous driving services worldwide, spanning existing deployments in China, Southeast Asia and the Middle East, as well as upcoming launches in broader Europe.

Young innovators awarded more than $100,000 for research on dementia-related proteins, alternatives to agricultural plastics and wildfire prevention

NEW YORK and NEW ORLEANS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in The Ensign Group, Inc. (NasdaqGS: ENSG) of a class action securities lawsuit.

A creative gift for wives, mothers and children turns indoor growing into a shared experience that continues long after the holiday season

NEW YORK and NEW ORLEANS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 8, 2026 to file lead plaintiff applications in a securities class action lawsuit against Millrose Propertiesif they purchased or otherwise acquired the Company’s securities between February 7, 2025 and October 2, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of Florida.

NEW YORK and NEW ORLEANS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Honeywell Aerospace, Inc. (“Honeywell Aerospace” or the “Company”) (NasdaqGS: HONA) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased or otherwise acquired the Company’s securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

NEW YORK and NEW ORLEANS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 14, 2026 to file lead plaintiff applications in a securities class action lawsuit against Gildan Activewear Inc. (“Gildan” or the “Company”) (NYSE: GIL), if they purchased or otherwise acquired the Company’s publicly traded securities between February 19, 2025 and June 15, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of New York.

NEW YORK and NEW ORLEANS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Duolingo, Inc. (NasdaqGS: DUOL) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Companyif they purchased or otherwise acquired the Company’s securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Delaware.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. 

BEIJING, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that latest data of orelabrutinib, its novel BTK inhibitor, were presented at the European Society for Medical Oncology (ESMO) Congress 2026.

COLUMBUS, Ohio, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) announced today the pricing of its previously announced underwritten public offering of 5,000,000 depositary shares (the “Depositary Shares”), each representing a 1/40th interest in a share of its 9.375% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series C, par value $0.01 per share (the “Series C Preferred Stock”), with a liquidation preference of $25 per Depositary Share (equivalent to $1,000 per share of Series C Preferred Stock). In addition, pursuant to the underwriting agreement, dated October 27, 2026, between the Company and Morgan Stanley & Co., LLC, Keefe, Bruyette & Woods, Inc., RBC Capital Markets, LLC, UBS Securities LLC and Wells Fargo Securities, LLC, as representatives of the underwriters named therein (the “Underwriters”), the Company granted the Underwriters an option to purchase up to an additional 750,000 Depositary Shares at the same price for a period of 30 days following October 27, 2026.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of FMC Corporation (“FMC” or the “Company”) (NYSE: FMC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kinross Gold Corporation (“Kinross” or the “Company”) (NYSE: KGC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of America’s Car-Mart, Inc. (“Car-Mart” or the “Company”) (NASDAQ: CRMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

CALGARY, Alberta, Oct. 27, 2026 (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the “Cautionary Statement Regarding Forward-Looking Information and Statements” later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnings before income taxes, (gain) loss on investments and other assets, finance charges, foreign exchange, gain on asset disposals and depreciation and amortization), Net Capital Spending, Working Capital and Total Long-Term Financial Liabilities. These terms do not have standardized meanings prescribed under International Financial Reporting Standards (IFRS) Accounting Standards and may not be comparable to similar measures used by other companies. See “Financial Measures and Ratios” later in this news release.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

CALGARY, Alberta, Oct. 27, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of TransAlta Corporation (TSX: TA) (NYSE: TAC) declared a quarterly dividend of $0.07 per common share payable on January 1, 2027, to shareholders of record at the close of business on December 1, 2026.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pasqal Holding SA (“Pasqal” or the “Company”) (NASDAQ: PSQL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mueller Industries, Inc. (“Mueller” or the “Company”) (NYSE: MLI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Silvercorp Metals Inc. (“Silvercorp” or the “Company”) (NYSE: SVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Concentrix Corporation (“Concentrix” or the “Company”) (NASDAQ: CNXC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of FreightCar America, Inc. (“FreightCar” or the “Company”) (NASDAQ: RAIL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lennar Corporation (“Lennar” or the “Company”) (NYSE: LEN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Job seekers who register for the Nov. 18 event will also receive complimentary admission to North America’s largest clean energy industry expo

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Six Flags Entertainment Corporation (“Six Flags” or the “Company”) (NYSE: FUN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. (“ClearPoint” or the “Company”) (NASDAQ: CLPT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Scholastic Corporation (“Scholastic” or the “Company”) (NASDAQ: SCHL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enova International, Inc. (“Enova” or the “Company”) (NYSE: ENVA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zscaler, Inc. (“Zscaler” or the “Company”) (NASDAQ: ZS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stitch Fix, Inc. (“Stitch Fix” or the “Company”) (NASDAQ: SFIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Securitize Corp.("Securitize" or the "Company") (NYSE:SECZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. (“Foghorn” or the “Company”) (NASDAQ: FHTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP. If you are an investor who believes that you may have incurred a loss regarding your Babcock & Wilcox Enterprises, Inc. securities ("B & W" or the "Company") (NYSE: BW); such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Deep Fission, Inc. (“Deep Fission” or the “Company”) (NASDAQ: FISN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ethos Technologies Inc. (“Ethos” or the “Company”) (NASDAQ: LIFE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

SAN FRANCISCO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kevin Caldwell, Ossium Health CEO, Co-Founder & President, has been named a winner of the 2026 Biocom Catalyst Award. Now in its 11th year, the Catalyst Awards honor emerging leaders under 40 who are shaping the future of life science in California and beyond. The awards are presented by Biocom, California’s largest life science membership association. Caldwell is one of 13 awardees in this year’s cohort, which spans AI-designed drugs, personalized cancer vaccines, gene and epigenetic editing, cell therapies, investors, and ecosystem builders.“Biocom represents the scientists, founders and investors who have made this state a center of life science innovation, so being recognized by this community means a great deal to me and to everyone at Ossium,” said Caldwell. “Joining a class of Catalysts working on gene editing, AI-designed medicines, and aging research signals that banked bone marrow is now part of the conversation about where medicine is headed.”The award recognizes Caldwell’s work building Ossium into the first bone marrow bank of its kind. For decades, scientists knew that deceased organ donors carry viable hematopoietic stem cells that could be used for bone marrow transplants. But connecting organ procurement organizations with transplant physicians was so complex that the idea was never put into practice. Caldwell co-founded Ossium to close that gap, bringing together organ recovery teams, scientists, federal agencies, and transplant physicians, groups that had never before coordinated at scale.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Duolingo, Inc. (“Duolingo” or the “Company”) (NASDAQ: DUOL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Webull Corporation (“Webull” or the “Company”) (NASDAQ: BULL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alphabet Inc. (“Alphabet” or the “Company”) (NASDAQ: GOOG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Vantive plans to expand operations, create 175 jobs over next four years

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Bank of America Corporation (“Bank of America” or the “Company”) (NYSE: BAC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fluence Energy, Inc. (“Fluence” or the “Company”) (NASDAQ: FLNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Endava Plc (“Endava” or the “Company”) (NYSE: DAVA).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against DICK’S Sporting Goods, Inc. (“Dick’s” or the “Company”) (NYSE: DKS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ryde Group Ltd. (“Ryde” or the “Company”) (NYSE: RYDE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Baidu, Inc. (“Baidu” or the “Company”) (NASDAQ: BIDU). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Yiren Digital Ltd. (“Yiren” or the “Company”) (NYSE: YRD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Dun & Bradstreet Holdings, Inc. (“Dun & Bradstreet” or the “Company”) (NYSE: DNB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.